Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation

References

• WolfPAAbbottRDKannelWBAtrial fibrillation: a major contributor to stroke in the elderly. The Framingham StudyArch Intern Med19871479156115643632164
   PubMedGoogle Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
   PubMed Web of Science ®Google Scholar
• HeeringaJvan der KuipDAHofmanAPrevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam StudyEur Heart J200627894995316527828
   PubMed Web of Science ®Google Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• NaccarelliGVVarkerHLinJSchulmanKLIncreasing prevalence of atrial fibrillation and flutter in the United StatesAm J Cardiol2009104111534153919932788
   PubMed Web of Science ®Google Scholar
• JørgensenHSNakayamaHReithJRaaschouHOOlsenTSAcute stroke with atrial fibrillation. The Copenhagen Stroke StudyStroke19962710176517698841326
   PubMed Web of Science ®Google Scholar
• LamassaMDi CarloAPracucciGCharacteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project)Stroke200132239239811157172
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• YouJJSingerDEHowardPAAntithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Supple531Se575S22315271
   PubMed Web of Science ®Google Scholar
• GageBFvan WalravenCPearceLSelecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirinCirculation2004110162287229215477396
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDS2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation2011123e269e36721382897
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• LipGYNieuwlaatRPistersRLaneDCrijnsHRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillationChest2010137226327219762550
   PubMed Web of Science ®Google Scholar
• CowanCHealiconRRobsonIThe use of anticoagulants in the management of atrial fibrillation among general practices in EnglandHeart201399161166117223393083
   PubMed Web of Science ®Google Scholar
• CammAJKirchhofPLipGYGuidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Europace201012101360142020876603
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• MantJHobbsFDRFletcherKWarfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trialLancet2007370958649350317693178
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group of the ACTIVE InvestigatorsClopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialLancet200636795261903191216765759
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)Chest20081336 Suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• HobbsFDRLeachIChallenges of stroke prevention in patients with atrial fibrillation in clinical practiceQJM2011104973974621750020
   PubMed Web of Science ®Google Scholar
• LinPJReviewing the reality: why we need to changeEur Heart J Suppl20057Suppl EE15E20
   Web of Science ®Google Scholar
• MavrakanasTBounameauxHThe potential role of new oral anticoagulants in the prevention and treatment of thromboembolismPharmacol Ther20111301465821185864
   PubMed Web of Science ®Google Scholar
• Eliquis® (apixaban) [Summary of Product Characteristics]Middlesex, UKBristol-Myers Squibb, Pfizer2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed January 6, 2015
   Google Scholar
• Pradaxa® (dabigatran etexilate) [Summary of Product Characteristics]Ingelheim, GermanyBoehringer Ingelheim International GmbH2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed January 6, 2015
   Google Scholar
• Xarelto® (rivaroxaban) [Summary of Product Characteristics.]Berlin, GermanyBayer Pharma AG2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed January 6, 2015
   Google Scholar
• Savaysa® (edoxaban) [Prescribing Information]Parsippany, NJDaiichi Sankyo Inc2015 Available from: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=trueAccessed January 12, 2015
   Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJEikelboomJWNovel oral Factor Xa and thrombin inhibitors in the management of thromboembolismAnnu Rev Med201162415721226611
   PubMed Web of Science ®Google Scholar
• AnsellJWarfarin versus new agents: interpreting the dataHematology Am Soc Hematol Educ Program2010201022122821239798
   PubMedGoogle Scholar
• HarderSRenal profiles of anticoagulantsJ Clin Pharmacol201252796497521610202
   PubMed Web of Science ®Google Scholar
• VermaAKBrightonTAThe direct factor Xa inhibitor rivaroxabanMed J Aust2009190737938319351313
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• ConnollySJWallentinLYusufSAdditional events in the RE-LY trialN Engl J Med20143711464146525251519
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med2010363191875187621047252
   PubMed Web of Science ®Google Scholar
• SteinerTRosandJDiringerMIntracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questionsStroke200637125626216339459
   PubMed Web of Science ®Google Scholar
• HealeyJSEikelboomJDouketisJPeriprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trialCirculation2012126334334822700854
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation20111232363237221576658
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• FoxKAAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J201132192387239421873708
   PubMed Web of Science ®Google Scholar
• SardarPChatterjeeSHerzogENairoozRMukherjeeDHalperinJLNovel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trialsCan J Cardiol201430888889725064581
   PubMed Web of Science ®Google Scholar
• DienerHCConnollySJEzekowitzMDDabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialLancet Neurol20109121157116321059484
   PubMed Web of Science ®Google Scholar
• HankeyGJPatelMRStevensSRRivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFLancet Neurol201211431532222402056
   PubMed Web of Science ®Google Scholar
• EastonJDLopesRDBahitMCApixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialLancet Neurol201211650351122572202
   PubMed Web of Science ®Google Scholar
• EzekowitzMDConnollySParekhARationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAm Heart J2009157580581019376304
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study InvestigatorsRivaroxaban – once-daily, oral, direct Factor Xa inhibition – compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF StudyAm Heart J201015934034720211293
   PubMed Web of Science ®Google Scholar
• LopesRDAlexanderJHAl-KhatibSMApixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationaleAm Heart J2010159333133920211292
   PubMed Web of Science ®Google Scholar
• SandercockPAGCounsellCKamalAKAnticoagulants for acute ischaemic strokeCochrane Database Syst Rev20084CD000024 Available from: http://dx.doi.org/10.1002/14651858.CD000024.pub3Accessed April 18, 2013
   Google Scholar
• HankeyGJAnticoagulant therapy for patients with ischaemic strokeNat Rev Neurol20128631932822565207
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace201315562565123625942
   PubMed Web of Science ®Google Scholar
• The European Stroke Organisation (ESO) Executive Committee, ESO Writing CommitteeGuidelines for management of ischaemic stroke and transient ischaemic attack 2008Cerebrovasc Dis200825545750718477843
   PubMed Web of Science ®Google Scholar
• HankeyGJJamrozikKBroadhurstRJLong-term risk of first recurrent stroke in the Perth Community Stroke StudyStroke19982912249125009836757
   PubMed Web of Science ®Google Scholar
• ArnoldAZMickMJMazurekRPLoopFDTrohmanRGRole of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutterJ Am Coll Cardiol19921948518551545081
   PubMed Web of Science ®Google Scholar
• CappatoREzekowitzMDKleinALRivaroxaban vs vitamin K antagonists for cardioversion in atrial fibrillationEur Heart J201435473346335525182247
   PubMed Web of Science ®Google Scholar
• PicciniJPStevensSRLokhnyginaYOutcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJ Am Coll Cardiol201361191998200623500298
   PubMed Web of Science ®Google Scholar
• NagarakantiREzekowitzMDOldgrenJDabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversionCirculation2011123213113621200007
   PubMed Web of Science ®Google Scholar
• FlakerGLopesRDAl KhatibSMEfficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)J Am Coll Cardiol201463111082108724211508
   PubMed Web of Science ®Google Scholar
• PfizerStudy of the blood thinner, apixaban, for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (cardioversion) (EMANATE) Available from: http://clinicaltrials.gov/show/NCT02100228. NLM identifier: NCT02100228Accessed November 10, 2014
   Google Scholar
• HammCWBassandJPAgewallSESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)Eur Heart J2011322999305421873419
   PubMed Web of Science ®Google Scholar
• StegPGJamesSKAtarDESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Eur Heart J201233202569261922922416
   PubMed Web of Science ®Google Scholar
• LipGYHWindeckerSHuberKManagement of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)Eur Heart J201435453155317925154388
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEMohanaveluSRivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialLancet2009374293819539361
   PubMed Web of Science ®Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
   PubMed Web of Science ®Google Scholar
• DansALConnollySJWallentinLConcomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialCirculation2013127563464023271794
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBDabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• HansenMLSørensenRClausenMTRisk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillationArch Intern Med2010170161433144120837828
   PubMed Web of Science ®Google Scholar
• Janssen Scientific Affairs LLCA study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) Available from: http://clinicaltrials.gov/ct2/show/NCT01830543. NLM identifier: NCT01830543Accessed November 10, 2014
   Google Scholar
• Boehringer IngelheimEvaluation of dual therapy with dabigatran vs triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI) Available from: https://clinicaltrials.gov/ct2/show/NCT02164864. NLM identifier: NCT02164864Accessed September 11, 2014
   Google Scholar
• PeacockWFGearhartMMMillsRMEmergency management of bleeding associated with old and new oral anticoagulantsClin Cardiol2012351273073722811404
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood2008111104871487918309033
   PubMed Web of Science ®Google Scholar
• KazmiRSLwaleedBANew anticoagulants: how to deal with treatment failure and bleeding complicationsBr J Clin Pharmacol201172459360321752066
   PubMed Web of Science ®Google Scholar
• Portola PharmaceuticalsA study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban Available from: http://clinicaltrials.gov/ct2/show/NCT02220725. NLM identifier: NCT02220725Accessed November 10, 2014
   Google Scholar
• Portola PharmaceuticalsA study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of apixaban Available from: http://clinicaltrials.gov/ct2/show/NCT02207725. NLM identifier: NCT02207725Accessed November 10, 2014
   Google Scholar
• Boehringer IngelheimReversal of dabigatran anticoagulant effect with idarucizumab Available from: http://clinicaltrials.gov/ct2/show/NCT02104947. NLM identifier: NCT02104947Accessed November 10, 2014
   Google Scholar
• MarluRHodajEParisAAlbaladejoPCrackowskiJLPernodGEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteersThromb Haemost2012108221722422627883
   PubMed Web of Science ®Google Scholar
• KhooTLWeatherburnCKershawGReddelCJCurnowJDunkleySThe use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatranInt J Lab Hematol201335222222423020832
   PubMed Web of Science ®Google Scholar
• KörberMKLangerEZiemerSPerzbornEGerickeCvon HeymannCMeasurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro studyClin Appl Thromb Hemost201420773574023832064
   PubMed Web of Science ®Google Scholar
• PragstIZeitlerSHDoerrBReversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit modelJ Thromb Haemost20121091841184822812619
   PubMed Web of Science ®Google Scholar
• GodierAMiclotALe BonniecBEvaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit modelAnesthesiology201211619410222042412
   PubMed Web of Science ®Google Scholar
• LambourneMDEltringham-SmithLJGataianceSArnoldDMCrowtherMASheffieldWPProthrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilateJ Thromb Haemost20121091830184022817470
   PubMed Web of Science ®Google Scholar
• PerzbornEGruberATinelHReversal of rivaroxaban anticoagulation by haemostatic agents in rats and primatesThromb Haemost2013110116217223636219
   PubMed Web of Science ®Google Scholar
• MartinACLe BonniecBFischerAMEvaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosisInt J Cardiol201316844228423323928345
   PubMed Web of Science ®Google Scholar
• ZhouWZornMNawrothPHemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxabanStroke201344377177823339956
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• LeviMMooreKTCastillejosCFComparison of three- and four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteersJ Thromb Haemost20141291428143624811969
   PubMed Web of Science ®Google Scholar
• PicciniJPGargJPatelMRManagement of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trialEur Heart J201435281873188024658769
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJForsterKPannachSRates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryBlood2014124695596224859362
   PubMed Web of Science ®Google Scholar
• SchulmanSCrowtherMAHow I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switchBlood2012119133016302322302737
   PubMed Web of Science ®Google Scholar
• KearonCHirshJManagement of anticoagulation before and after elective surgeryN Engl J Med199733621150615119154771
   PubMed Web of Science ®Google Scholar
• HirshJFusterVAnsellJHalperinJLAmerican Heart Association/American College of Cardiology Foundation guide to warfarin therapyCirculation2003107121692171112668507
   PubMed Web of Science ®Google Scholar
• StampfussJKubitzaDBeckaMMueckWThe effect of food on the absorption and pharmacokinetics of rivaroxabanInt J Clin Pharmacol Ther201351754956123458226
   PubMed Web of Science ®Google Scholar
• MatsushimaNLeeFSatoTWeissDMendellJBioavailability and safety of the Factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjectsClin Pharm Drug Dev201324358366
   PubMed Web of Science ®Google Scholar
• MendellJZahirHMatsushimaNDrug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral Factor Xa inhibitorAm J Cardiovasc Drugs201313533134223784266
   PubMed Web of Science ®Google Scholar
• EikelboomJWConnollySJBrueckmannMDabigatran versus warfarin in patients with mechanical heart valvesN Engl J Med2013369131206121423991661
   PubMed Web of Science ®Google Scholar